231 related articles for article (PubMed ID: 26304171)
1. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
Booka E; Imamura CK; Takeuchi H; Hamamoto Y; Gomi D; Mizukami T; Ichiyama T; Tateishi K; Takahashi T; Kawakubo H; Soejima K; Boku N; Tanigawara Y; Kitagawa Y
Gastric Cancer; 2016 Jul; 19(3):876-86. PubMed ID: 26304171
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application.
Takeuchi M; Imamura CK; Booka E; Takeuchi H; Mizukami T; Kawakami T; Funakoshi T; Wakuda K; Aoki Y; Hamamoto Y; Kitago M; Kawakubo H; Boku N; Tanigawara Y; Kitagawa Y
Cancer Sci; 2021 Feb; 112(2):751-759. PubMed ID: 33277781
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
[TBL] [Abstract][Full Text] [Related]
6. Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
Jeung HC; Rha SY; Shin SJ; Ahn JB; Noh SH; Roh JK; Chung HC
Jpn J Clin Oncol; 2010 Jan; 40(1):29-35. PubMed ID: 19880858
[TBL] [Abstract][Full Text] [Related]
7. Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer.
Shiroyama T; Kijima T; Komuta K; Yamamoto S; Minami S; Ogata Y; Okafuji K; Imamura F; Hirashima T; Tachibana I; Kawase I; Kumanogoh A
Cancer Chemother Pharmacol; 2012 Dec; 70(6):783-9. PubMed ID: 22960985
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of S-1 in patients in whom inulin clearance was measured.
Ando Y; Kawada K; Inada M; Morita S; Mitsuma A; Yasuda Y; Hiramatsu M; Fujimoto Y; Fujita K
Oncology; 2012; 83(1):38-44. PubMed ID: 22722580
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
10. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.
Kim WY; Nakata B; Hirakawa K
Cancer Sci; 2007 Oct; 98(10):1604-8. PubMed ID: 17683513
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function.
Goto K; Fujiwara Y; Isobe T; Chayahara N; Kiyota N; Mukohara T; Tsubata Y; Hotta T; Tamura K; Yamamoto N; Minami H
Cancer Sci; 2019 Jun; 110(6):1987-1994. PubMed ID: 30989775
[TBL] [Abstract][Full Text] [Related]
12. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
[TBL] [Abstract][Full Text] [Related]
13. Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas.
Fujita K; Ichikawa W; Yamamoto W; Endo H; Nagashima F; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Sasaki Y
Ann Oncol; 2009 May; 20(5):946-9. PubMed ID: 19150953
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 5-FU plasma concentration by 13C breath test in patients treated with oral 5-FU analogs.
Higashida M; Matsumoto H; Kubota H; Murakami H; Kawabe Y; Nakashima H; Oka Y; Okumura H; Nakamura M; Hirai T
Anticancer Res; 2012 Dec; 32(12):5407-14. PubMed ID: 23225444
[TBL] [Abstract][Full Text] [Related]
15. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
[TBL] [Abstract][Full Text] [Related]
16. [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
Yamamoto K; Imamura H; Furukawa H; Kishimoto T; Tanaka J; Oshiro R; Tatsuta M; Masutani S; Fukunaga M; Nakayama T; Takemoto H; Kondo M; Kamigaki S; Kawasaki T
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1748-51. PubMed ID: 16315929
[TBL] [Abstract][Full Text] [Related]
17. Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T
Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
20. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T
Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
